Figure 3
From: Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury
Serum active GLP-1, SDF-1α and PDGF concentration in control and linagliptin-treated mice. (A) Serum active GLP-1 concentration in control (n =14) and linagliptin-treated mice (n =14), (B) serum SDF-1α concentration in control (n =9) and linagliptin-treated mice (n =10), and (C) serum PDGF concentration in control (n =9) and linagliptin-treated mice (n =8), assessed using ELISA kits. Data are mean ± SEM. *p <0.05 vs. control.